Letter | Published:

Pre- and postsynaptic components in effect of drugs with α adrenoceptor affinity

Abstract

ACTIVATION of α adrenoceptors on noradrenergic nerve endings is thought to inhibit the release of noradrenaline by nerve impulses1,2. The existence of a presynaptic receptor system introduces a new concept to the pharmacology of drugs with affinity for α adrenoceptors. Only when the presynaptic nerve does not secrete, as for example in the absence of impulses, may one assume a priori that the observed postsynaptic effects of these drugs result from their interaction with postsynaptic receptors. When action potentials arrive at the nerve endings, noradrenaline is released and keeps the postsynaptic receptors in a certain degree of excitation. Drugs which activate α adrenoceptors may enhance this excitation by their postsynaptic effects, or reduce it by their presynaptic actions. Conversely, α adrenolytic drugs may diminish the excitation by postsynaptic blockade, or enhance it by facilitation of release. If the postsynaptic receptors are of the β type, the prevailing action is presynaptic; thus, drugs which activate a adrenoceptors reduce3–5, whereas, less regularly, α adrenolytic drugs increase6 cardiac responses to sympathetic nerve stimulation. If the postsynaptic receptors are of the α type, the prevailing effect of a adrenolytic drugs is postsynaptic blockade7; we report here that the effects of drugs which activate α adrenoceptors are diverse.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Langer, S. Z., Biochem. Pharmac., 23, 1793–1800 (1974).

  2. 2

    Starke, K., in Frontiers in Catecholamine Research (edit. by Usdin, E., and Synder, S. H.), 561–565 (Pergamon, Oxford, 1973).

  3. 3

    Starke, K., Archs Pharmac., 274, 18–45 (1972).

  4. 4

    Armstrong, J. M., and Boura, A. L. A., Br. J. Pharmac., 47, 850–852 (1973).

  5. 5

    Vizi, S., Somogyi, G. T., Hadhäzy, P., and Knoll, J., Archs Pharmac., 280, 79–91 (1973).

  6. 6

    Farah, M. B., and Langer, S. Z., Br. J. Pharmac., 52, 549–557 (1974).

  7. 7

    Dubocovich, M. L., and Langer, S. Z., J. Physiol. Lond., 237, 505–519 (1974).

  8. 8

    Starke, K., Montel, H., Gayk, W., and Merker, R., Archs Pharmac., 285, 133–150 (1974).

  9. 9

    Su, C., and Bevan, J. A., J. Pharmac. exp. Ther., 172, 62–68 (1970).

  10. 10

    Ambache, N., and Zar, M. A., J. Physiol. Lond., 216, 359–389 (1971).

  11. 11

    Farnebo, L. O., and Malmfors, T., Acta Physiol. scand., Suppl., 371, 1–18 (1971).

  12. 12

    Sjöstrand, N. O., Acta Physiol. scand., 89, 10–18 (1973).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.